A 20-year evidence-based experience of the evolving medicine regulation in Zanzibar.

IF 3.3 Q1 HEALTH POLICY & SERVICES Journal of Pharmaceutical Policy and Practice Pub Date : 2024-11-07 eCollection Date: 2024-01-01 DOI:10.1080/20523211.2024.2421273
Burhani Simai, Daniel Joshua, Salma Ali, Bora Lichanda, Sharifa Ali, Amne Issa, Heber Anandan, Raphael Zozimus Sangeda
{"title":"A 20-year evidence-based experience of the evolving medicine regulation in Zanzibar.","authors":"Burhani Simai, Daniel Joshua, Salma Ali, Bora Lichanda, Sharifa Ali, Amne Issa, Heber Anandan, Raphael Zozimus Sangeda","doi":"10.1080/20523211.2024.2421273","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Access to medicine is crucial for the effective functioning of healthcare systems. A robust regulatory framework is necessary to ensure the safety, effectiveness, and availability. However, weak regulatory frameworks persist in many low- and middle-income countries, leasing to the circulation of falsified and substandard medicines as well as anti-competitive restrictions on registering poor-quality medicines, which poses a significant public health threat. This study evaluated the evolution of Zanzibar's medicine regulatory system over the past two decades and identified the key factors contributing to its success by elaborating on the Zanzibar Food and Drug Agency, seeking the expertise of regional, continental, and global experts to assess its regulatory capacity and maturity level.</p><p><strong>Methods: </strong>This study was conducted at the Zanzibar Food and Drug Agency (ZFDA) in Unguja, Zanzibar, using a retrospective cross-sectional review and qualitative approach. It thoroughly reviewed relevant regulatory documents, including Acts, policies, guidelines, and assessment reports. Data were collected using a standardised checklist and analysed to uncover patterns and insights regarding the evolution of Zanzibar's medicine regulatory system.</p><p><strong>Results: </strong>This study revealed substantial legal provisions, organisational development, strategic planning, and resource allocation improvements. Notable achievements include establishing a structured organisational framework, developing a comprehensive strategic plan, and implementing a Quality Management System (ISO 9001:2015 certified). The ZFDA also addressed human resource limitations by creating job descriptions and a staff scheme of service, enhancing financial resources through revised fee regulations and government support, and improving infrastructure with new office and laboratory facilities.</p><p><strong>Conclusion: </strong>Zanzibar's medicine regulations have evolved significantly, with marked regulatory capacity and infrastructure improvements. Future efforts should address the remaining challenges and foster collaboration with regional and international bodies to ensure the continued evolution and effectiveness of Zanzibar's medicine regulatory framework.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":"17 1","pages":"2421273"},"PeriodicalIF":3.3000,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11544740/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Policy and Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/20523211.2024.2421273","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"HEALTH POLICY & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Access to medicine is crucial for the effective functioning of healthcare systems. A robust regulatory framework is necessary to ensure the safety, effectiveness, and availability. However, weak regulatory frameworks persist in many low- and middle-income countries, leasing to the circulation of falsified and substandard medicines as well as anti-competitive restrictions on registering poor-quality medicines, which poses a significant public health threat. This study evaluated the evolution of Zanzibar's medicine regulatory system over the past two decades and identified the key factors contributing to its success by elaborating on the Zanzibar Food and Drug Agency, seeking the expertise of regional, continental, and global experts to assess its regulatory capacity and maturity level.

Methods: This study was conducted at the Zanzibar Food and Drug Agency (ZFDA) in Unguja, Zanzibar, using a retrospective cross-sectional review and qualitative approach. It thoroughly reviewed relevant regulatory documents, including Acts, policies, guidelines, and assessment reports. Data were collected using a standardised checklist and analysed to uncover patterns and insights regarding the evolution of Zanzibar's medicine regulatory system.

Results: This study revealed substantial legal provisions, organisational development, strategic planning, and resource allocation improvements. Notable achievements include establishing a structured organisational framework, developing a comprehensive strategic plan, and implementing a Quality Management System (ISO 9001:2015 certified). The ZFDA also addressed human resource limitations by creating job descriptions and a staff scheme of service, enhancing financial resources through revised fee regulations and government support, and improving infrastructure with new office and laboratory facilities.

Conclusion: Zanzibar's medicine regulations have evolved significantly, with marked regulatory capacity and infrastructure improvements. Future efforts should address the remaining challenges and foster collaboration with regional and international bodies to ensure the continued evolution and effectiveness of Zanzibar's medicine regulatory framework.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
桑给巴尔不断发展的医药法规的 20 年循证经验。
背景:获得药品对于医疗保健系统的有效运作至关重要。要确保药品的安全性、有效性和可获得性,就必须有一个健全的监管框架。然而,许多中低收入国家的监管框架仍然薄弱,导致假冒伪劣药品的流通以及对劣质药品注册的反竞争限制,对公众健康构成了严重威胁。本研究评估了桑给巴尔药品监管体系在过去二十年中的演变,并通过对桑给巴尔食品药品管理局的详细阐述,确定了其成功的关键因素,同时寻求地区、非洲大陆和全球专家的专业知识,以评估其监管能力和成熟度:本研究在桑给巴尔温古贾的桑给巴尔食品药品管理局(ZFDA)进行,采用了回顾性横向审查和定性方法。它全面审查了相关监管文件,包括法案、政策、指南和评估报告。使用标准化清单收集数据并进行分析,以揭示桑给巴尔医药监管体系演变的模式和启示:这项研究揭示了在法律规定、组织发展、战略规划和资源分配方面的重大改进。显著成就包括建立了结构化的组织框架,制定了全面的战略计划,并实施了质量管理体系(已通过 ISO 9001:2015 认证)。桑给巴尔药品管理局还通过制定职位说明和员工服务计划来解决人力资源限制问题,通过修订收费条例和政府支持来增加财政资源,并通过新建办公和实验室设施来改善基础设施:桑给巴尔的医药法规有了显著发展,监管能力和基础设施得到明显改善。未来的努力应解决剩余的挑战,并促进与地区和国际机构的合作,以确保桑给巴尔医药监管框架的持续发展和有效性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Pharmaceutical Policy and Practice
Journal of Pharmaceutical Policy and Practice Health Professions-Pharmacy
CiteScore
4.70
自引率
9.50%
发文量
81
审稿时长
14 weeks
期刊最新文献
Pharmaceutical multinational corporations (MNCs) and their exit from low and middle income countries (LMICs): analysing the causes and consequences. Prescriber perceptions of the safety and efficacy of unfractionated heparin versus low molecular weight heparin in the acute treatment phase: a qualitative study. Prevalence and management of anemia and impact of treatment burden on health-related quality of life in chronic kidney disease and dialysis patients. Costs of the Supervision, Performance Assessment and Recognition Strategy (SPARS) for improving medicines management in Nepal. A 20-year evidence-based experience of the evolving medicine regulation in Zanzibar.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1